Citi added an “upside 90-day catalyst watch” on shares of Natera (NTRA) while keeping a Buy rating on the name with a $300 price target ahead of the Q1 report. Citi believes Natera’s fundamentals have momentum exiting 2025 while the shares have pulled back significantly.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target lowered to $250 from $260 at Evercore ISI
- Natera Expands Board, Appoints Eric Rubin as Director
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Natera announces publications on clinical utility of Signatera
- GeneDx data could support improved coverage, says Craig-Hallum